Temporal association of cannabis use with symptoms in individuals at clinical high risk for psychosis

Schizophrenia Research

Volumn 106, Issue 2-3, 2008, Pages 286-293

  Corcoran, Cheryl M ^a   Kimhy, David ^a   Stanford, Arielle ^a   Khan, Shamir ^a   Walsh, Julie ^a   Thompson, Judy ^a   Schobel, Scott ^a   Harkavy Friedman, Jill ^a   Goetz, Ray ^a   Colibazzi, Tiziano ^a   Cressman, Victoria ^a   Malaspina, Dolores ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

Cannabis; Longitudinal; Prodrome; Psychosis; Risk

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CANNABIS ADDICTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; FEMALE; FOLLOW UP; HUMAN; MALE; PERCEPTION DISORDER; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOSIS; RISK ASSESSMENT; RISK FACTOR; SCHOOL CHILD; SUBSTANCE ABUSE;

ADULT; ANXIETY DISORDERS; COMORBIDITY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MARIJUANA ABUSE; PERCEPTUAL DISORDERS; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RISK FACTORS; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX;

EID: 56049094316     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2008.08.008     Document Type: Article

References (39)

1. Arsenault L., Cannon M., Poulton R., Murray R., Caspi A., and Moffitt T.E. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. B.M.J. 325 (2002) 1212-1213
2. Arseneault L., Cannon M., Witton J., and Murray R.M. Causal association between cannabis and psychosis: examination of the evidence. Br. J. Psychiatry 184 (2004) 110-117
3. Cannon T.D., Cadenhead K., Cornblatt B., Woods S.W., Addington J., Walker E., Seidman L.J., Perkins D., Tsuang M., McGlashan T., and Heinssen R. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch. Gen. Psychiatry 65 1 (2008) 28-37
4. Caspi A., Moffitt T.E., Cannon M., McClay J., Murray R., Harrington H., Taylor A., Arseneault L., Williams B., Braithwaite A., Poulton R., and Craig I.W. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene × environment interaction. Biol. Psychiatry 57 10 (2005) 1117-1127
5. Cuffel B.J., Heithoff K.A., and Lawson W. Correlates of patterns of substance abuse among patients with schizophrenia. Hosp. Community Psychiatry 44 3 (1993) 247-251
6. Diggle P.J., Liang K.Y., and Zeger S.L. Analysis of Longitudinal Data (1994), Clarendon Press, Oxford
7. D'Souza D.C., Perry E., MacDougall L., Ammerman Y., Cooper T., Wu Y.T., Braley G., Gueorguieva R., and Krystal J.H. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29 8 (2004) 1558-1572
8. Hambrecht M., and Häfner H. Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective. Aust. N. Z. J. Psychiatry 34 3 (2000) 468-475
9. Hamilton M. Hamilton Anxiety Scale. In: Guy W. (Ed). ECDEU Assessment Manual for Psychopharmacology (1976), NIMH, Rockville, MD
10. Haroun N., Dunn L., Haroun A., and Cadenhead K.S. Risk and protection in prodromal schizophrenia: ethical implications for clinical practice and future research. Schizophr. Bull. 32 1 (2006) 166-178
11. Haroun N., Dunn L., Haroun A., and Cadenhead K.S. Risk and protection in prodromal schizophrenia: ethical implications for clinical practice and future research. Schizophr. Bull. 32 (2006) 166-178
12. Hawkins K.A., McGlashan T.H., Quinlan D., Miller T.J., Perkins D.O., Zipursky R.B., Addington J., and Woods S.W. Factorial structure of the scale of prodromal symptoms. Schizophr. Res. 68 2-3 (2004) 339-347
13. Henquet C., Rosa A., Krabbendam L., Papiol S., Fananas L., Drukker M., Ramaekers J.G., and van Os J. An experimental study of catechol-O-methyltransferase Val(158)Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology 31 12 (2006) 2748-2757
14. Hides L., Dawe S., Kavanagh D.J., and Young R.M. Psychotic symptom and cannabis relapse in recent-onset psychosis. Prospective study. Br. J. Psychiatry 189 (2006) 137-143
15. Kaufman J., Birmaher B., Brent D., Rao U., Flynn C., Moreci P., Williamson D., and Ryan N. Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): initial reliability and validity data. J. Am. Acad. Child Adolesc. Psychiatry 36 (1997) 980-988
16. Kendler K.S., Gallagher T.J., Abelson J.M., and Kessler R.C. Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample. The National Comorbidity Survey. Arch. Gen. Psychiatry 53 11 (1996) 1022-1031
17. Kristensen K., and Cadenhead K.S. Cannabis abuse and risk for psychosis in a prodromal sample. Psychiatry Res. 151 1-2 (2007) 151-154
18. Koethe D., Gerth C.W., Neatby M.A., Haensel A., Thies M., Schneider U., Emrich H.M., Klosterkötter J., Schultze-Lutter F., and Leweke F.M. Disturbances of visual information processing in early states of psychosis and experimental delta-9-tetrahydrocannabinol altered states of consciousness. Schizophr. Res. 88 1-3 (2006) 142-150
19. Lencz T., Smith C.W., Auther A., Correll C.U., and Cornblatt B. Nonspecific and attenuated negative symptoms in patients at clinical high-risk for schizophrenia. Schizophr. Res. 68 1 (2004) 37-48
20. Lencz T., Smith C.W., Auther A., Correll C.U., and Cornblatt B. Nonspecific and attenuated negative symptoms in patients at clinical high-risk for schizophrenia. Schizophr. Res. 68 (2004) 37-48
21. Meyer S.E., Bearden C.E., Lux S.R., Gordon J.L., Johnson J.K., O'Brien M.P., Niendam T.A., Loewy R.L., Ventura J., and Cannon T.D. The psychosis prodrome in adolescent patients viewed through the lens of DSM-IV. J. Child Adolesc. Psychopharmacol. 15 3 (2005) 434-451
22. Miller P., Lawrie S.M., Hodges A., Clafferty R., Cosway R., and Johnstone E.C. Genetic liability, illicit drug use, life stress and psychotic symptoms: preliminary findings from the Edinburgh study of people at high risk for schizophrenia. Soc. Psychiatry Psychiatr. Epidemiol. 36 7 (2001) 338-342
23. Miller T.J., McGlashan T.H., Rosen J.L., Cadenhead K., Cannon T., Ventura J., McFarlane W., Perkins D.O., Pearlson G.D., and Woods S.W. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr. Bull. 29 4 (2003) 703-715
24. Miller P.M., Johnstone E.C., Lawrie S.M., and Owens D.G.C. Substance use, psychiatric symptoms and the onset of schizophrenic illness. J. Subst. Abuse 11 2 (2006) 101-113
25. Moore T.H.M., Zammit S., Lingford-Hughes A., Barnes T.R.E., Jones P.B., Burke M., and Lewis G. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370 (2007) 319-328
26. Murray R.M., Morrison P.D., Henquet C., and Di Forti M. Cannabis, the mind and society: the hash realities. Nat. Rev. Neurosci. 8 11 (2007) 885-895
27. Nurnberger Jr. J.I., Blehar M.C., Kaufmann C.A., York-Cooler C., Simpson S.G., Harkavy-Friedman J., Severe J.B., Malaspina D., and Reich T. Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Arch. Gen. Psychiatry 51 11 (1994) 849-859
28. Pencer A., and Addington J. Substance use and cognition in early psychosis. J. Psychiatry Neurosci. 28 1 (2003) 48-54
29. Phillips L.J., Curry C., Yung A.R., Yuen H.P., Adlard S., and McGorry P.D. Cannabis use is not associated with the development of psychosis in an 'ultra' high-risk group. Aust. N. Z. J. Psychiatry 36 6 (2002) 800-806
30. Preda A., Miller T.J., Rosen J.L., Somjee L., McGlashan T.H., and Woods S.W. Treatment histories of patients with a syndrome putatively prodromal to schizophrenia. Psychiatr. Serv. 53 3 (2002) 342-344
31. Regier D.A., Farmer M.E., Rae D.S., Locke B.Z., Keith S.J., Judd L.L., and Goodwin F.K. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. J.A.M.A. 264 19 (1990) 2511-2518
32. Rosen J.L., Miller T.J., D'Andrea J.T., McGlashan T.H., and Woods S.W. Comorbid diagnoses in patients meeting criteria for the schizophrenia prodrome. Schizophr. Res. 85 (2006) 124-131
33. Sevy S., Robinson D.G., Holloway S., Alvir J.M., Woerner M.G., Bilder R., Goldman R., Lieberman J., and Kane J. Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder. Acta Psychiatr. Scand. 104 5 (2001) 367-374
34. Stirling J., Lewis S., Hopkins R., and White C. Cannabis use prior to first onset psychosis predicts spared neurocognition at 10-year follow-up. Schizophr. Res. 75 (2005) 135-137
35. Thomas H. A community survey of adverse effects of cannabis use. Drug Alcohol Depend. 42 3 (1996) 201-207
36. Van Mastrigt S., Addington J., and Addington D. Substance misuse at presentation to an early psychosis program. Soc. Psychiatry Epidemiol. 156 4 (2003) 319-327
37. Verdoux H., Gindre C., Sorbara F., Tournier M., and Swendsen J.D. Effects of cannabis and psychosis vulnerability in daily life: an experience sampling test study. Psychol. Med. 33 1 (2003) 23-32
38. Voruganti L.N., Slomka P., Zabel P., Mattar A., and Awad A.G. Cannabis induced dopamine release: an in-vivo SPECT study. Psychiatry Res. 107 3 (2001) 173-177
39. Yung A.R., Phillips L.J., Yuen H.P., and McGorry P.D. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr. Res. 67 2-3 (2004) 131-142